Enveric Biosciences, Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
29405E208
SEDOL
N/A
CIK
0000890821
www.enveric.com
LEI:
FIGI: BBG000BBQ281
ENVB
Enveric Biosciences, Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Biotechnology
NAME
Enveric Biosciences, Inc.
ISIN
US29405E2081
TICKER
ENVB
MIC
XNAS
REUTERS
ENVB.OQ
BLOOMBERG
ENVB US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Mon, 06.01.2025
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will participate in a panel discussion and present at the Sachs Ass...
Enveric Biosciences
Mon, 02.12.2024
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued two U.S. Patents, Nos. 1...
Enveric Biosciences
Mon, 25.11.2024
Enveric Biosciences
US29405E2081
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small molecule therapeutics for the treatment of depression, anxiety, and other psychiatric disorders, today announced the completion of preclinical pharmacokinetic (“PK”) studies in rat and dog furthe...
Enveric Biosciences
Thu, 14.11.2024
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the third quarter ended September 30, 202...
Enveric Biosciences
Tue, 12.11.2024
Enveric Biosciences
US29405E2081
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company has executed a licensing agreement with MycoMedica Life Sciences, out-lic...
Enveric Biosciences
Tue, 15.10.2024
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced positive results for preclinical safety and pharmacology studies, which evaluated off-target i...
Enveric Biosciences
Thu, 26.09.2024
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it is presenting research describing the Company’s identification of EB-003 as its lead d...
Enveric Biosciences
Wed, 25.09.2024
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that research highlighting the Company’s lead compound, EB-003, is being presented at the 7th ...
Enveric Biosciences
Wed, 04.09.2024
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announced that Joseph Tucker, Ph.D., Chief Executive Officer, will deliver a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference being ...
Enveric Biosciences
Tue, 13.08.2024
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, and Aries Science & Technology (“Aries”), a developer of encapsulation technologies, today announced that Patent No. 12,059,393 was issued on August 13, 2024, to Enveric’...
Enveric Biosciences
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
